PortfoliosLab logoPortfoliosLab logo
ISIN
US19624Y2000

Highlights

Market Cap
$12.85B
Enterprise Value
$16.73B
EPS (TTM)
DKK 0.92
PE Ratio
40.49
Total Revenue (TTM)
DKK 26.54B
Gross Profit (TTM)
DKK 17.24B
EBITDA (TTM)
DKK 11.88B
Year Range
$5.65 - $10.03
Target Price
$14.45
ROA (TTM)
4.44%
ROE (TTM)
16.14%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Coloplast A

Often compared with CLPBY:
CLPBY vs. SCHGCLPBY vs. BABA

Performance

CLPBY Performance Chart

Coloplast A (CLPBY) is down 32.1% since the beginning of the year. At $6 per share, CLPBY is trading 43.2% below its 52-week high of $10. Investors who bought $1,000 worth of CLPBY shares 5 years ago would now be looking at an investment worth $416.


Loading charts...

S&P 500 Index

Returns By Period

Coloplast A (CLPBY) has returned -32.13% so far this year and -36.91% over the past 12 months. Over the last ten years, CLPBY has returned -0.12% per year, falling short of the S&P 500 Index benchmark, which averaged 13.71% annually.


Coloplast A

1D
-0.18%
1M
-9.67%
YTD
-32.13%
6M
-32.05%
1Y
-36.91%
3Y*
-20.68%
5Y*
-16.08%
10Y*
-0.12%

Benchmark (S&P 500 Index)

1D
-1.44%
1M
-1.45%
YTD
7.60%
6M
6.59%
1Y
22.24%
3Y*
19.20%
5Y*
11.54%
10Y*
13.71%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CLPBY Monthly Returns History

Based on dividend-adjusted daily data since Jan 13, 2014, CLPBY's average daily return is +0.02%, while the average monthly return is +0.28%. At this rate, an investment would double in approximately 20.7 years.

Historically, 53% of months were positive and 47% were negative. The best month was Feb 2014 with a return of +18.4%, while the worst month was Jan 2022 at -17.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CLPBY closed higher 47% of trading days. The best single day was Feb 9, 2024 with a return of +10.2%, while the worst single day was Nov 2, 2017 at -12.0%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-0.59%-8.76%-10.89%-10.63%2.19%-8.06%-32.13%
20255.99%-7.91%-0.94%7.43%-14.13%-1.35%-2.74%4.56%-11.51%6.33%1.32%-4.61%-18.64%
20240.69%15.33%1.05%-9.90%-0.49%0.17%8.11%4.67%-4.26%-4.34%0.96%-12.34%-3.34%
20234.30%-5.36%14.13%9.98%-11.83%-0.67%-0.88%-8.20%-7.44%-0.66%11.90%0.19%1.79%
2022-17.86%2.75%1.54%-10.99%-11.89%-4.14%3.08%-2.05%-11.12%8.97%5.85%0.65%-32.87%
2021-2.42%4.00%-2.62%10.30%-4.35%2.97%12.55%-5.66%-10.08%4.41%0.21%9.75%17.70%

Benchmark Metrics

Coloplast A has an annualized alpha of -1.73%, beta of 0.46, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since January 13, 2014.

  • This stock participated in 104.82% of S&P 500 Index downside but only 57.60% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.46 may look defensive, but with R2 of 0.09 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-1.73%
Beta
0.46
0.09
Upside Capture
57.60%
Downside Capture
104.82%

Return for Risk

Risk / Return Rank

CLPBY ranks 3 for risk / return — in the bottom 3% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


CLPBY Risk / Return Rank: 33
Overall Rank
CLPBY Sharpe Ratio Rank: 11
Sharpe Ratio Rank
CLPBY Sortino Ratio Rank: 33
Sortino Ratio Rank
CLPBY Omega Ratio Rank: 44
Omega Ratio Rank
CLPBY Calmar Ratio Rank: 66
Calmar Ratio Rank
CLPBY Martin Ratio Rank: 22
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Coloplast A (CLPBY) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CLPBYBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-3.16

Sortino ratioReturn per unit of downside risk

-4.48

Omega ratioGain probability vs. loss probability

0.77

1.32

-0.56

Calmar ratioReturn relative to maximum drawdown

-0.92

2.46

-3.38

Martin ratioReturn relative to average drawdown

-1.86

10.92

-12.77

Dividends

Dividend History

Coloplast A provided a 6.28% dividend yield over the last twelve months, with an annual payout of $0.36 per share. The company has been increasing its dividends for 4 consecutive years.


1.50%2.00%2.50%3.00%3.50%4.00%$0.00$0.10$0.20$0.30$0.4020152016201720182019202020212022202320242025
Dividends
Dividend Yield
PeriodTTM20252024202320222021202020192018201720162015
Dividend$0.36$0.35$0.32$0.31$0.28$0.26$0.29$0.22$0.15$0.12$0.11$0.10

Dividend yield

6.28%4.17%2.91%2.66%2.41%1.49%1.91%1.75%1.58%1.55%1.64%1.25%

Monthly Dividends

The table displays the monthly dividend distributions for Coloplast A. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.00$0.00$0.00$0.00$0.08$0.00$0.08
2025$0.00$0.00$0.00$0.00$0.08$0.00$0.00$0.00$0.00$0.00$0.00$0.28$0.35
2024$0.00$0.00$0.00$0.00$0.07$0.00$0.00$0.00$0.00$0.00$0.00$0.24$0.32
2023$0.00$0.00$0.00$0.00$0.07$0.00$0.00$0.00$0.00$0.00$0.00$0.23$0.31
2022$0.00$0.00$0.00$0.00$0.07$0.00$0.00$0.00$0.00$0.00$0.00$0.21$0.28
2021$0.00$0.00$0.00$0.00$0.05$0.00$0.00$0.00$0.00$0.00$0.00$0.21$0.26

Dividend Yield & Payout


Dividend Yield

Coloplast A has a dividend yield of 6.28%, which means its dividend payment is significantly above the market average.

Payout Ratio

Coloplast A has a payout ratio of 255.85%, which is above the market average. This might signify the company's strong earnings or financial health. However, it could also hint at a more mature business phase with potentially slower growth.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Coloplast A. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Coloplast A was 65.21%, occurring on Jun 23, 2026. The portfolio has not yet recovered.

The current Coloplast A drawdown is 65.21%.


Related event

Drawdown

Fall

Recovery

Underwater

2026 bear market2026
-65.21%Jun 2026
4y 10mo
4y 10moAug 2021 - now
2016 bear market2016
-31.08%Nov 2016
2y 5mo6mo 11d
2y 12moJun 2014 - Jun 2017
2021 bear market2021
-20.67%Mar 2021
7mo 3d4mo 13d
11mo 16dAug 2020 - Jul 2021
Rate-hike selloffLate 2018
-18.51%Nov 2018
3mo 8d5mo 1d
8mo 9dJul 2018 - Apr 2019
2014 correction2014
-15.95%Mar 2014
14d1mo 22d
2mo 6dMar 2014 - May 2014

Drawdown Indicators


CLPBYBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-65.21%

-56.78%

-8.43%

Max Drawdown (1Y)

Largest decline over 1 year

-40.09%

-9.10%

-30.99%

Max Drawdown (3Y)

Largest decline over 3 years

-56.66%

-18.90%

-37.76%

Max Drawdown (5Y)

Largest decline over 5 years

-65.21%

-25.43%

-39.78%

Max Drawdown (10Y)

Largest decline over 10 years

-65.21%

-33.92%

-31.29%

Current Drawdown

Current decline from peak

-65.21%

-3.21%

-62.00%

Average Drawdown

Average peak-to-trough decline

-19.31%

-10.71%

-8.60%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.90%

2.04%

+17.86%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Coloplast A over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Coloplast A is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for CLPBY, comparing it with other companies in the Medical Instruments & Supplies industry. Currently, CLPBY has a P/E ratio of 40.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for CLPBY relative to other companies in the Medical Instruments & Supplies industry. Currently, CLPBY has a P/S ratio of 3.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for CLPBY in comparison with other companies in the Medical Instruments & Supplies industry. Currently, CLPBY has a P/B value of 6.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with CLPBY

Add Coloplast A to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with CLPBY